ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1627

Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure

Chien-Chih Lai1, Yi-Syuan Sun 1 and Chang-Youh Tsai 2, 1Division of Allergy, Immunology, Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China), 2Division of Allergy, Immunology & Rheumatology/Taipei Veterans General Hospital, Taipei, Taiwan (Republic of China)

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: bronchoalveolar lavage fluid and morbidity and mortality, pneumonia, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: SLE – Clinical Poster II: Comorbidities

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: To evaluate the pathogens from bronchoalveolar lavage fluid (BALF) and risk factors of mortality in SLE patients with pneumonia and respiratory failure.

Methods: Twenty-four SLE patients were enrolled. Clinical characteristics, laboratory profiles at admission, and microbiology from BALF were presented. We also performed univariable analyses for mortality risk.

Results: Among the 24 patients (21 women, median age: 46.5 years; duration of SLE: 11 years), 8 of them had septic shock, and 9 of them died within 30 days. All of them were supported with mechanical ventilations with a medial duration of 11 days (Table 1). Pathogens identified from BALF were Pneumocystis jiroveci pneumonia (PJP) in 12 patients (50%), Cytomegalovirus in 7 patients (29.2%), bacteria in 11 patients (45.8%). Thirteen patients (54.2%) had blood stream infections, the leading causes were cytomegalovirus in 8 patients (33.3%) and E. coli in 5 patients (20.8%). Univariable analysis indicated that the presence of thrombocytopenia (odd ratio [OR]: 8.0, 95% confidence interval [CI]: 1.23–52.25), bacteremia before or after one month of endotracheal intubation (OR: 8.0, 95% CI: 1.23–52.5), and PJP (OR: 7.0, 95% CI: 1.04–46.95) were risk factors for 30-day mortality (Table 2). Kaplan-Meier analysis also confirmed the risk of 30-mortality in patients with thrombocytopenia and bacteremia (Figure 1).

Conclusion: The prevalence of cytomegalovirus and Pneumocystis jiroveci was high in BALF from SLE patients encountered pneumonia and respiratory failure. BALF analysis facilitated a pathogen-specific treatment, which may lower the overall mortality rate in such vulnerable patients. Thrombocytopenia, bacteremia, and PJP may indicate an increased 30-day mortality rate.


SLE pneumonia BAL table 1

Table 1


SLE pneumonia BAL table 2

Table 2

Figure 1


Disclosure: C. Lai, None; Y. Sun, None; C. Tsai, None.

To cite this abstract in AMA style:

Lai C, Sun Y, Tsai C. Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/bronchoalveolar-lavage-fluid-analysis-and-mortality-risk-in-systemic-lupus-erythematosus-patients-with-pneumonia-and-respiratory-failure/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bronchoalveolar-lavage-fluid-analysis-and-mortality-risk-in-systemic-lupus-erythematosus-patients-with-pneumonia-and-respiratory-failure/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology